Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 10,940 other HR bills in the 119th — cohort avg 30d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2026 · third_quarter · Health Issues
Lobbied in support of universal health care, including the Medicare for All Act (H.R. 3069) and the Medicines for the People Act (H.R. 7854). Lobbied in support of reforms to Medicare Advantage, including H.R 9544, and in support of universal health care.
Client expense: $10,000 · Firm income: Not reported
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES
2026 · second_quarter · Pharmacy
Lobbied in support of public manufacturing of prescription drugs (H.R.7854 - Medicines for the People Act).
Client expense: $10,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES
2026 · second_quarter · Health Issues
Lobbied in support of universal health care, including Medicare for All (Medicare for All Act, H.R. 3069) and the Medicine for the People Act (H.R. 7854). Lobbied in support of reforms to Medicare Advantage. Lobbied in support of the Protecting Health Care and Lowering Costs Act (H.R. 4849) and extending Affordable Care Act subsidies, including S. 3385.
Client expense: $10,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Health Issues
Issues related to the following bills: S.1040: Drug Competition Enhancement Act - Prohibits product hopping which stifles generic and biosimilar competition to extend monopoly pricing. It explicitly defines and regulates these under the Federal Trade Commission S.1041: Affordable Prescriptions for Patients Act - Limits how brand-name drug companies use patents to block competition from cheaper biosimilar or generic versions of biologic drugs by reducing the number of patents drug companies can use to delay cheaper alternatives from entering the market - making medicines more affordable and accessible. A brand-name drug company could then only sue using up to 20 patents when a competitor applies to sell a biosimilar. S.1095: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act - Stops pharmaceutical companies from abusing the citizen petition process to file sham petitions to block or delay generic or biosimilar drug approvals. S.1096: Preserve Access to Affordable Generics and Biosimilars Act - Bans pay-to-delay or killer acquisitions. Brand name drug manufacturers cannot pay generic manufacturers to delay-to-market any competitive biosimilar or interchangeable biologic products. S.2276/HR 3269: ETHIC Act - A bill to address patent thickets. HR 7854: Medicines for the People Act - To amend the Public Health Service Act to establish a National Institute for Biomedical Research and Development, and for other purposes. S.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Additionally, issues related to an FTC settlement.
Client expense: Not reported · Firm income: Not reported
Government targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Pharmacy
Lobbied in support of a public option for Pharmaceuticals (H.R.7854 - Medicines for the People Act).
Client expense: $10,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES
| Democratic |
| FL |
| Summer L. Lee | Democratic | PA |